JUN 3 0 2006

I hereby certify that this compound being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313 on Jove 27, 2006

INFORMATION DISCLOSURE STATEMENT Examining Group 2183 Patent Application

Docket No. ARS-106 Serial No. 10/517,726

Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit

2183

Applicants

Amanda Proudfoot, Marie Kosco-Vilbois

Serial No

10/517,726

Filed

December 10, 2004

Conf. No.

6045

For

Novel Antagonists of CXCR3-Binding CXC Chemokines

Mail Stop Amendment Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

The patent application referred to above was filed in the U.S. Patent Office as a national application under 35 USC §371. Applicants have been notified that a copy of the International Search Report has been made available in the national stage file as indicated on the Notice of Acceptance of the Application Under 35 USC 371 (Form PCT/DO/EO/903). The Notice does not indicate whether copies of the references cited in the International Search Report were received by the Patent Office. Therefore, copies of the references cited in the International Search Report are enclosed for the Examiner's convenience. However, Applicants have not submitted copies of the U.S. patents and U.S. published Patent Application cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

In accordance with 37 CFR §1.56, Applicants hereby request that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

Applicants respectfully assert that the substantive provisions of 37 CFR \$\$1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332 Phone No.: 352-375-8100

Fax No.: 352-372-5800 Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of cited references.

Under the Paperwork Reduced 1995, no p

Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
1995. no persons are required to respond to a collection of information unless is contains a valid OMB

Substitute for form	1449A/PTO			Complete if Known		
			.ne	Application Number 10/517,726		
	TION DISCL			Filing Date	December 10, 2004	
STATEMENT BY APPLICANT (use as many sheets as necessary)				First Named Inventor	Amanda Proudfoot	
				Art Unit	2183	
				Examiner Name		
Sheet	1	of	2	Attorney Docket Number	ARS-106	

			U.S. PATENT DO	OCUMENTS		
Examiner City Initials* No.		Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/BH/	U1	US-5,739,103	04-14-1998	Rollins et al.	All	
	U2	US-2002-018776 A1	02-14-2002	Hancock	All	
	U3_	US-6,140,064	10-31-2000	Loetscher et al.	All	
	U4	US-5,977,334	11-02-1999	Ransohoff et al.	All	
	U5	US-5,656,724	08-12-1997	Daly et al.	All	
V	U6	US-5,969,093	10-19-1999	Jacobs et al.	All	
	U7	US-				
	U8	US-				
	U9	US-	- 20			

FOREIGN PATENT DOCUMENTS							
		Foreign Patent Document	Publication Date		Pagas, Columns, Lines.	T ⁴	
Examiner Initials'	No.1	Country Code 3 - Number 4 - Kind Code5 (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passagas or Relevant Figures Appear		
/BH/	F1	WO 02/43758 A2	06-06-2002	Schering Corp.	All		
/BH/	F2	WO 02/04015 A1 (CD-ROM)	01-17-2002	Gryphon Therapeutics, Inc.	All	Г	
	F3						
	F4						
	F5					Г	
	F6						
	F7	4 1 1		-			

Examiner	/Bruce Hissong/	Date	07/18/2008
Signature		Considered	0771072000

"EXAMINET: Inflat if reference considered, whether or not clation is in conformance with MPEP 408. Draw line through clatic in from in conformance and not considered, include copy of this form with next communication to applicant "Applicant" unique clation designation under opposite 36 extind Codes of USFTO Patient Decuments at <u>www.uspto.go</u> or MPEPPot 104. "Enter Office that issued the document, by the thousand rove (MPE) Some and the communication of the year of the region of the Empirication of the year of fixed document by the appropriate symbols as an included on the document under VMPO Standard ST. 16 if possible. "Applicant is to place a check mark here if English language

This collection of stormation is required by 37 CER 1.97 and 1.98. The information is required to obtain or return a barefit by the public which is to file (and by the USFTO to proceed) an application. Confidentiality is opened by 39 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 50 boars to complete including gathering, preparing, and submitting the completed application form to the USFTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patient and Trademark Office, P.O. Box 1450, Alexandria, VA. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, VA. 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. ĎEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB
control number

				Complete if Known		
	e for form 1449B/PTO	60	OCUDE	Application Number	10/517,726	
INFORMATION DISCLOSURE				Filing Date December 10, 2004		
STATEMENT BY APPLICANT			LICANI	First Named Inventor Amanda Proudfoot		
(use as many sheets as necessary)				Group Art Unit 2183		
				Examiner Name		
Sheet	t 2 of 2		Attorney Docket Number	ARS-106		

NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the Cite Examiner T² item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Initials* No. number(s), publisher, city and/or country where published. LOERTSCHER, P. et al. "The Ligands of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10, Are /BH/ Natural Antagonists for CCR3" The Journal of Biological Chemistry, February 2, 2001, pp. 2986-R1 2991, Vol. 276, No. 5. R2 R4 R5 R6 R7 R9 R10 R11 R12

Examiner	/Bruce Hissong/	Date	07/18/2008
Signature	ľ	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include convict this form with next communication to applicant

and not considered. Include copy of this form with next communication to applicant.

*Applicant's unjuse clutation essignation number (optional, "Applicant's unjuse caneds mark here if English language Translation is attached.

This collection of information is required by 3° CFR 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Condificationally in governed by 3° US.C. 122 and 3° CFR 114. This collection is estimated to take 2 hoursplant, programming preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, about be sent to the Chief Information (C. U.S. Patent and Trademark Office, P.O. Box 1490, Alexandria, VA. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22315-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.